Incannex Healthcare received $59.0 million financing, positive Phase 2 results with synthetic psilocybin.

From GlobeNewswire: 2024-09-30 16:01:00

Incannex Healthcare Inc received up to $59.0 million USD through strategic financing from Arena Investors. Positive results from a Phase 2 clinical trial showed reduced anxiety scores with synthetic psilocybin in combination with psychotherapy. The dosing of the RePOSA Phase 2/3 clinical trial for obstructive sleep apnea has commenced. The FDA has cleared the initiation of another Phase 2 clinical trial for PSX-001. Incannex has completed redomiciliation to the US and listed shares on Nasdaq as “IXHL.” The company reported fiscal full-year financial results and operational highlights, including the opening of Clarion Clinics for psychedelic-assisted psychotherapy in Australia. The completion of dosing in a bioavailability/bioequivalence clinical trial for IHL-42X was announced, as well as positive results from the PsiGAD1 Phase 2 clinical trial. Top-line data from the RePOSA trial is expected in the first half of 2025, with results from the BA/BE trial expected in 2024.



Read more at GlobeNewswire:: Incannex Healthcare Inc. Reports Fiscal Full Year 2024